Exscientia plc

Exscientia ended Q1 2024 with $417 million in cash. Operating cash burn was $39 million in the first quarter of 2024, down 29% from $55 million in the first quarter of last year. Management said the company now has cash runway well into 2027 without additional business development, versus prior guidance of well into 2026. No revenue, EPS, or gross margin figures were stated in the call. Forward-looking guidance included annualized savings of at least $40 million beginning in 2025, Q3 2024 IND submission for EXS74539, first clinical site opening toward the end of 2024, and a planned early-2025 clinical trial start for EXS73565.

Dave Hallett framed 2024 as a year of opportunity and repeatedly emphasized that Exscientia’s AI-driven platform plus automation is improving speed, cost efficiency, and the probability of success. He highlighted multiple clinical shots on goal this year, especially CDK7, the positive early Phase I results for the BMS-partnered PKC theta program, and the planned advancement of LSD1 and MALT1 into the clinic. His tone was confident and strategic, but he also made clear the company is pruning legacy activities to stay focused on its core platform, pipeline, and partnerships.

Ben Taylor emphasized partnership monetization and cost discipline, saying the company has brought in almost $230 million from partnerships over the last few years and expects more near-term inflows. Financially, he pointed to $417 million in cash and a 29% reduction in operating cash burn to $39 million, while reiterating that annual operating cash burn should be less than last year. He also said the new operating model should deliver more than $40 million in annual cash savings from 2025 onward, helping extend runway well into 2027 without additional financing or business development.

Analysts focused on CDK7 positioning, especially monotherapy versus combination use, toxicity management, and the likely indication/combination partner. Management said CDK7 should show some monotherapy activity but will “almost certainly” be used in combination, with toxicity—especially GI toxicity—seen as the key issue; possible paths mentioned included ER-positive/HER2-negative CDK4/6-refractory breast cancer with fulvestrant or lung cancer with a PD-L1, and possibly immunotherapy combinations. Questions also touched on partnership strategy and the cost cuts; management said they remain open to both traditional target-based pharma collaborations and earlier-stage biotech/start-up deals, while technology-partner discussions are centered on supporting the automation studio. On PKC theta, management said the program is progressing in BMS’s portfolio and that more could be shared in coming quarters.